Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 302

1.

Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19).

Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, Oczkowski S, Levy MM, Derde L, Dzierba A, Du B, Aboodi M, Wunsch H, Cecconi M, Koh Y, Chertow DS, Maitland K, Alshamsi F, Belley-Cote E, Greco M, Laundy M, Morgan JS, Kesecioglu J, McGeer A, Mermel L, Mammen MJ, Alexander PE, Arrington A, Centofanti JE, Citerio G, Baw B, Memish ZA, Hammond N, Hayden FG, Evans L, Rhodes A.

Crit Care Med. 2020 Mar 27. doi: 10.1097/CCM.0000000000004363. [Epub ahead of print]

PMID:
32224769
2.

Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19).

Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, Oczkowski S, Levy MM, Derde L, Dzierba A, Du B, Aboodi M, Wunsch H, Cecconi M, Koh Y, Chertow DS, Maitland K, Alshamsi F, Belley-Cote E, Greco M, Laundy M, Morgan JS, Kesecioglu J, McGeer A, Mermel L, Mammen MJ, Alexander PE, Arrington A, Centofanti JE, Citerio G, Baw B, Memish ZA, Hammond N, Hayden FG, Evans L, Rhodes A.

Intensive Care Med. 2020 Mar 28. doi: 10.1007/s00134-020-06022-5. [Epub ahead of print]

PMID:
32222812
3.

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C.

N Engl J Med. 2020 Mar 18. doi: 10.1056/NEJMoa2001282. [Epub ahead of print]

PMID:
32187464
4.

Influenza Therapeutics in Clinical Practice-Challenges and Recent Advances.

Beigel JH, Hayden FG.

Cold Spring Harb Perspect Med. 2020 Feb 10. pii: a038463. doi: 10.1101/cshperspect.a038463. [Epub ahead of print]

PMID:
32041763
5.

Critical care management of adults with community-acquired severe respiratory viral infection.

Arabi YM, Fowler R, Hayden FG.

Intensive Care Med. 2020 Feb;46(2):315-328. doi: 10.1007/s00134-020-05943-5. Epub 2020 Feb 10. Review.

6.

A novel coronavirus outbreak of global health concern.

Wang C, Horby PW, Hayden FG, Gao GF.

Lancet. 2020 Feb 15;395(10223):470-473. doi: 10.1016/S0140-6736(20)30185-9. Epub 2020 Jan 24. No abstract available. Erratum in: Lancet. 2020 Jan 29;:.

7.

RSV Antivirals: Problems and Progress.

Hayden FG, Whitley RJ.

J Infect Dis. 2020 Jan 24. pii: jiaa029. doi: 10.1093/infdis/jiaa029. [Epub ahead of print] No abstract available.

PMID:
31974551
8.

Comment to: Baloxavir efficacy in North American Adults.

Portsmouth S, Kawaguchi K, Uehara T, Hayden FG.

Eur J Intern Med. 2020 Feb;72:99-101. doi: 10.1016/j.ejim.2019.11.005. Epub 2020 Jan 15. No abstract available.

PMID:
31954593
9.

Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study.

Arabi YM, Shalhoub S, Mandourah Y, Al-Hameed F, Al-Omari A, Al Qasim E, Jose J, Alraddadi B, Almotairi A, Al Khatib K, Abdulmomen A, Qushmaq I, Sindi AA, Mady A, Solaiman O, Al-Raddadi R, Maghrabi K, Ragab A, Al Mekhlafi GA, Balkhy HH, Al Harthy A, Kharaba A, Gramish JA, Al-Aithan AM, Al-Dawood A, Merson L, Hayden FG, Fowler R.

Clin Infect Dis. 2019 Jun 25. pii: ciz544. doi: 10.1093/cid/ciz544. [Epub ahead of print]

PMID:
31925415
10.

Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial.

Arabi YM, Asiri AY, Assiri AM, Aziz Jokhdar HA, Alothman A, Balkhy HH, AlJohani S, Al Harbi S, Kojan S, Al Jeraisy M, Deeb AM, Memish ZA, Ghazal S, Al Faraj S, Al-Hameed F, AlSaedi A, Mandourah Y, Al Mekhlafi GA, Sherbeeni NM, Elzein FE, Almotairi A, Al Bshabshe A, Kharaba A, Jose J, Al Harthy A, Al Sulaiman M, Mady A, Fowler RA, Hayden FG, Al-Dawood A, Abdelzaher M, Bajhmom W, Hussein MA; and the Saudi Critical Care Trials group.

Trials. 2020 Jan 3;21(1):8. doi: 10.1186/s13063-019-3846-x.

11.

Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection.

Wang Y, Fan G, Salam A, Horby P, Hayden FG, Chen C, Pan J, Zheng J, Lu B, Guo L, Wang C, Cao B; CAP-China Network.

J Infect Dis. 2019 Dec 11. pii: jiz656. doi: 10.1093/infdis/jiz656. [Epub ahead of print]

PMID:
31822885
12.

Baloxavir marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes.

Hirotsu N, Sakaguchi H, Sato C, Ishibashi T, Baba K, Omoto S, Shishido T, Tsuchiya K, Hayden FG, Uehara T, Watanabe A.

Clin Infect Dis. 2019 Sep 20. pii: ciz908. doi: 10.1093/cid/ciz908. [Epub ahead of print]

PMID:
31538644
13.

Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza.

Uehara T, Hayden FG, Kawaguchi K, Omoto S, Hurt AC, De Jong MD, Hirotsu N, Sugaya N, Lee N, Baba K, Shishido T, Tsuchiya K, Portsmouth S, Kida H.

J Infect Dis. 2020 Jan 14;221(3):346-355. doi: 10.1093/infdis/jiz244.

PMID:
31309975
14.

Antivirals targeting the polymerase complex of influenza viruses.

Mifsud EJ, Hayden FG, Hurt AC.

Antiviral Res. 2019 Sep;169:104545. doi: 10.1016/j.antiviral.2019.104545. Epub 2019 Jun 25. Review.

15.

Noninvasive ventilation in critically ill patients with the Middle East respiratory syndrome.

Alraddadi BM, Qushmaq I, Al-Hameed FM, Mandourah Y, Almekhlafi GA, Jose J, Al-Omari A, Kharaba A, Almotairi A, Al Khatib K, Shalhoub S, Abdulmomen A, Mady A, Solaiman O, Al-Aithan AM, Al-Raddadi R, Ragab A, Balkhy HH, Al Harthy A, Sadat M, Tlayjeh H, Merson L, Hayden FG, Fowler RA, Arabi YM; Saudi Critical Care Trials Group.

Influenza Other Respir Viruses. 2019 Jul;13(4):382-390. doi: 10.1111/irv.12635. Epub 2019 Mar 18.

16.

Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.

Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, Gravenstein S, Hayden FG, Harper SA, Hirshon JM, Ison MG, Johnston BL, Knight SL, McGeer A, Riley LE, Wolfe CR, Alexander PE, Pavia AT.

Clin Infect Dis. 2019 Mar 5;68(6):895-902. doi: 10.1093/cid/ciy874. No abstract available.

17.

Influenza virus polymerase inhibitors in clinical development.

Hayden FG, Shindo N.

Curr Opin Infect Dis. 2019 Apr;32(2):176-186. doi: 10.1097/QCO.0000000000000532.

18.

Macrolides in critically ill patients with Middle East Respiratory Syndrome.

Arabi YM, Deeb AM, Al-Hameed F, Mandourah Y, Almekhlafi GA, Sindi AA, Al-Omari A, Shalhoub S, Mady A, Alraddadi B, Almotairi A, Al Khatib K, Abdulmomen A, Qushmaq I, Solaiman O, Al-Aithan AM, Al-Raddadi R, Ragab A, Al Harthy A, Kharaba A, Jose J, Dabbagh T, Fowler RA, Balkhy HH, Merson L, Hayden FG; Saudi Critical Care Trials group.

Int J Infect Dis. 2019 Apr;81:184-190. doi: 10.1016/j.ijid.2019.01.041. Epub 2019 Jan 25.

19.

Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.

Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, Gravenstein S, Hayden FG, Harper SA, Hirshon JM, Ison MG, Johnston BL, Knight SL, McGeer A, Riley LE, Wolfe CR, Alexander PE, Pavia AT.

Clin Infect Dis. 2019 Mar 5;68(6):e1-e47. doi: 10.1093/cid/ciy866. Erratum in: Clin Infect Dis. 2019 May 2;68(10):1790.

20.

Critically ill healthcare workers with the middle east respiratory syndrome (MERS): A multicenter study.

Shalhoub S, Al-Hameed F, Mandourah Y, Balkhy HH, Al-Omari A, Al Mekhlafi GA, Kharaba A, Alraddadi B, Almotairi A, Al Khatib K, Abdulmomen A, Qushmaq I, Mady A, Solaiman O, Al-Aithan AM, Al-Raddadi R, Ragab A, Al Harthy A, Al Qasim E, Jose J, Al-Ghamdi G, Merson L, Fowler R, Hayden FG, Arabi YM.

PLoS One. 2018 Nov 15;13(11):e0206831. doi: 10.1371/journal.pone.0206831. eCollection 2018.

21.

Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.

Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, Ishida T, Sekino H, Yamada K, Portsmouth S, Kawaguchi K, Shishido T, Arai M, Tsuchiya K, Uehara T, Watanabe A; Baloxavir Marboxil Investigators Group.

N Engl J Med. 2018 Sep 6;379(10):913-923. doi: 10.1056/NEJMoa1716197.

22.

Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial.

Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, AlJohani S, Al Harbi S, Kojan S, Al Jeraisy M, Deeb AM, Assiri AM, Al-Hameed F, AlSaedi A, Mandourah Y, Almekhlafi GA, Sherbeeni NM, Elzein FE, Memon J, Taha Y, Almotairi A, Maghrabi KA, Qushmaq I, Al Bshabshe A, Kharaba A, Shalhoub S, Jose J, Fowler RA, Hayden FG, Hussein MA; And the MIRACLE trial group.

Trials. 2018 Jan 30;19(1):81. doi: 10.1186/s13063-017-2427-0.

23.

Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome.

Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, Jose J, Pinto R, Al-Omari A, Kharaba A, Almotairi A, Al Khatib K, Alraddadi B, Shalhoub S, Abdulmomen A, Qushmaq I, Mady A, Solaiman O, Al-Aithan AM, Al-Raddadi R, Ragab A, Balkhy HH, Al Harthy A, Deeb AM, Al Mutairi H, Al-Dawood A, Merson L, Hayden FG, Fowler RA; Saudi Critical Care Trial Group.

Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767. doi: 10.1164/rccm.201706-1172OC.

PMID:
29161116
24.

Ebola virus disease: an update on post-exposure prophylaxis.

Fischer WA 2nd, Vetter P, Bausch DG, Burgess T, Davey RT Jr, Fowler R, Hayden FG, Jahrling PB, Kalil AC, Mayers DL, Mehta AK, Uyeki TM, Jacobs M.

Lancet Infect Dis. 2018 Jun;18(6):e183-e192. doi: 10.1016/S1473-3099(17)30677-1. Epub 2017 Nov 15. Review.

25.

Critically Ill Patients With the Middle East Respiratory Syndrome: A Multicenter Retrospective Cohort Study.

Arabi YM, Al-Omari A, Mandourah Y, Al-Hameed F, Sindi AA, Alraddadi B, Shalhoub S, Almotairi A, Al Khatib K, Abdulmomen A, Qushmaq I, Mady A, Solaiman O, Al-Aithan AM, Al-Raddadi R, Ragab A, Al Mekhlafi GA, Al Harthy A, Kharaba A, Ahmadi MA, Sadat M, Mutairi HA, Qasim EA, Jose J, Nasim M, Al-Dawood A, Merson L, Fowler R, Hayden FG, Balkhy HH; Saudi Critical Care Trial Group.

Crit Care Med. 2017 Oct;45(10):1683-1695. doi: 10.1097/CCM.0000000000002621.

PMID:
28787295
26.

The hidden burden of influenza: A review of the extra-pulmonary complications of influenza infection.

Sellers SA, Hagan RS, Hayden FG, Fischer WA 2nd.

Influenza Other Respir Viruses. 2017 Sep;11(5):372-393. doi: 10.1111/irv.12470. Review.

27.

Serotherapy for patients with severe influenza.

Scott D, Epstein JS, Hayden FG.

Lancet Respir Med. 2017 Jun;5(6):462-464. doi: 10.1016/S2213-2600(17)30173-X. Epub 2017 May 15. No abstract available.

PMID:
28522353
28.

Middle East Respiratory Syndrome.

Arabi YM, Balkhy HH, Hayden FG, Bouchama A, Luke T, Baillie JK, Al-Omari A, Hajeer AH, Senga M, Denison MR, Nguyen-Van-Tam JS, Shindo N, Bermingham A, Chappell JD, Van Kerkhove MD, Fowler RA.

N Engl J Med. 2017 Feb 9;376(6):584-594. doi: 10.1056/NEJMsr1408795. No abstract available.

29.

Experimental Therapies for Ebola Virus Disease: What Have We Learned?

Hayden FG, Friede M, Bausch DG.

J Infect Dis. 2017 Jan 15;215(2):167-170. doi: 10.1093/infdis/jiw496. No abstract available. Erratum in: J Infect Dis. 2017 May 15;215(10):1629.

30.

Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia.

Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, Al-Dawood A, Al-Qahtani S, Al-Omari A, Al-Hameed F, Hayden FG, Fowler R, Bouchama A, Shindo N, Al-Khairy K, Carson G, Taha Y, Sadat M, Alahmadi M.

Emerg Infect Dis. 2016 Sep;22(9):1554-61. doi: 10.3201/eid2209.151164.

31.

The search for therapeutic options for Middle East Respiratory Syndrome (MERS).

Arabi YM, Balkhy HH, Hayden FG, Hui DS, Van Kerkhove MD, Fowler RA.

J Infect Public Health. 2016 May-Jun;9(3):213-5. doi: 10.1016/j.jiph.2016.03.004. Epub 2016 Mar 31. No abstract available.

32.

Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol.

Arabi Y, Balkhy H, Hajeer AH, Bouchama A, Hayden FG, Al-Omari A, Al-Hameed FM, Taha Y, Shindo N, Whitehead J, Merson L, AlJohani S, Al-Khairy K, Carson G, Luke TC, Hensley L, Al-Dawood A, Al-Qahtani S, Modjarrad K, Sadat M, Rohde G, Leport C, Fowler R.

Springerplus. 2015 Nov 19;4:709. doi: 10.1186/s40064-015-1490-9. eCollection 2015.

33.

Infectious Diseases Society of America and Gain-of-Function Experiments With Pathogens Having Pandemic Potential.

Frank GM, Adalja A, Barbour A, Casadevall A, Dormitzer PR, Duchin J, Hayden FG, Hirsch MS, Hynes NA, Lipsitch M, Pavia AT, Relman DA.

J Infect Dis. 2016 May 1;213(9):1359-61. doi: 10.1093/infdis/jiv474. Epub 2015 Sep 27. No abstract available.

PMID:
26416656
34.

Design, recruitment, and microbiological considerations in human challenge studies.

Darton TC, Blohmke CJ, Moorthy VS, Altmann DM, Hayden FG, Clutterbuck EA, Levine MM, Hill AV, Pollard AJ.

Lancet Infect Dis. 2015 Jul;15(7):840-51. doi: 10.1016/S1473-3099(15)00068-7. Epub 2015 May 27. Review.

PMID:
26026195
35.

Challenges and opportunities in developing respiratory syncytial virus therapeutics.

Simões EA, DeVincenzo JP, Boeckh M, Bont L, Crowe JE Jr, Griffiths P, Hayden FG, Hodinka RL, Smyth RL, Spencer K, Thirstrup S, Walsh EE, Whitley RJ.

J Infect Dis. 2015 Mar 15;211 Suppl 1:S1-S20. doi: 10.1093/infdis/jiu828.

36.

Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical management.

Hurt AC, Hui DS, Hay A, Hayden FG.

Influenza Other Respir Viruses. 2015 Jan;9(1):20-31. doi: 10.1111/irv.12293. Epub 2014 Nov 15. Review.

37.

Antiviral combinations for severe influenza.

Dunning J, Baillie JK, Cao B, Hayden FG; International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC).

Lancet Infect Dis. 2014 Dec;14(12):1259-70. doi: 10.1016/S1473-3099(14)70821-7. Epub 2014 Sep 8. Review. Erratum in: Lancet Infect Dis. 2014 Dec;14(12):1174.

PMID:
25213733
38.

Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options.

Zumla A, Memish ZA, Maeurer M, Bates M, Mwaba P, Al-Tawfiq JA, Denning DW, Hayden FG, Hui DS.

Lancet Infect Dis. 2014 Nov;14(11):1136-1149. doi: 10.1016/S1473-3099(14)70828-X. Epub 2014 Sep 1. Review.

PMID:
25189352
39.

Towards improving clinical management of Middle East respiratory syndrome coronavirus infection.

Hayden FG, Farrar J, Peiris JS.

Lancet Infect Dis. 2014 Jul;14(7):544-6. doi: 10.1016/S1473-3099(14)70793-5. No abstract available.

PMID:
24964934
40.

Editorial commentary: Host and viral factors in emergent influenza virus infections.

Hui DS, Hayden FG.

Clin Infect Dis. 2014 Apr;58(8):1104-6. doi: 10.1093/cid/ciu054. Epub 2014 Jan 31. No abstract available.

41.

Open source clinical science for emerging infections.

Dunning JW, Merson L, Rohde GGU, Gao Z, Semple MG, Tran D, Gordon A, Olliaro PL, Khoo SH, Bruzzone R, Horby P, Cobb JP, Longuere KS, Kellam P, Nichol A, Brett S, Everett D, Walsh TS, Hien TT, Yu H, Zambon M, Ruiz-Palacios G, Lang T, Akhvlediani T; ISARIC Working Group 3, ISARIC Council, Hayden FG, Marshall J, Webb S, Angus DC, Shindo N, van der Werf S, Openshaw PJM, Farrar J, Carson G, Baillie JK.

Lancet Infect Dis. 2014 Jan;14(1):8-9. doi: 10.1016/S1473-3099(13)70327-X. No abstract available.

PMID:
24355025
42.

Advances in antivirals for non-influenza respiratory virus infections.

Hayden FG.

Influenza Other Respir Viruses. 2013 Nov;7 Suppl 3:36-43. doi: 10.1111/irv.12173. Review.

43.

Second isirv antiviral group conference: overview.

Hurt AC, Ison MG, Hayden FG, Hay AJ.

Influenza Other Respir Viruses. 2013 Nov;7 Suppl 3:1-7. doi: 10.1111/irv.12207. No abstract available.

44.

Therapy of H7N9 pneumonia: current perspectives.

Cao B, Hayden FG.

Expert Rev Anti Infect Ther. 2013 Nov;11(11):1123-6. doi: 10.1586/14787210.2013.847787. No abstract available.

PMID:
24151830
45.

Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus.

Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, Li PT, Dai J, Mok FK, Chen H, Hayden FG, Yuen KY.

J Infect. 2013 Dec;67(6):606-16. doi: 10.1016/j.jinf.2013.09.029. Epub 2013 Oct 3.

PMID:
24096239
46.

A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections.

Lee N, Hui DS, Zuo Z, Ngai KL, Lui GC, Wo SK, Tam WW, Chan MC, Wong BC, Wong RY, Choi KW, Sin WW, Lee EL, Tomlinson B, Hayden FG, Chan PK.

Clin Infect Dis. 2013 Dec;57(11):1511-9. doi: 10.1093/cid/cit597. Epub 2013 Sep 17.

PMID:
24046309
47.

Oseltamivir resistance during treatment of H7N9 infection.

Hay AJ, Hayden FG.

Lancet. 2013 Jun 29;381(9885):2230-2. doi: 10.1016/S0140-6736(13)61209-X. No abstract available.

PMID:
23809549
48.

Epidemic influenza--responding to the expected but unpredictable.

Bresee J, Hayden FG.

N Engl J Med. 2013 Feb 14;368(7):589-92. doi: 10.1056/NEJMp1300375. Epub 2013 Jan 23. No abstract available.

49.

Newer influenza antivirals, biotherapeutics and combinations.

Hayden FG.

Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1:63-75. doi: 10.1111/irv.12045. Review.

50.

The beneficial effects of neuraminidase inhibitor drug therapy on severe patient outcomes during the 2009-2010 influenza A virus subtype H1N1 pandemic.

Aoki FY, Hayden FG.

J Infect Dis. 2013 Feb 15;207(4):547-9. doi: 10.1093/infdis/jis727. Epub 2012 Nov 29. No abstract available.

PMID:
23204176

Supplemental Content

Loading ...
Support Center